Chip Parkinson

Gifthealth's Chip Parkinson shares his outlook on direct-to-patient models in specialty, regulation and platform design heading into 2027.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Four pharma commerce voices check back in at the midpoint of 2026 to see how their dealmaking, patient access and commercialization predictions have held up.

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

Gifthealth's Chip Parkinson revisits his 2026 outlook on the direct-to-patient model, and what's developed in H1.

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

Third in a three-part series

Second in a three-part series. Next up: The DTP Balance Sheet - Access Up, Friction Down

First in a three-part series. Next up: what is DTP and who benefits from it?